Search and volunteer to participate in these available studies at UB. Your participation in research doesn't just benefit you, it helps advance healthcare for our entire community.

Highlighted Searches
Search Clinical Trials
Filter on any fields below
?
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
Showing 31 - 40 of 316 Clinical Trials
Description:
This study enrolls students who participate in the after-school program at a local Buffalo community location. The purpose of this study is to look at reading and literacy skills after a computer based newsletter program. Read More
Eligibility:
-Children ages 10-13.
-Must be in the after-school program at a participating local Buffalo community center in grades 6-8.
-Must have access to a computer: laptop, Chromebook, or desktop with the capability to download Zoom.
-Must have internet access at home or center.
Description:
This study enrolls older adults with Alzheimer’s Disease (AD). The purpose of the study is to learn whether the study drug, GV-971, can help the thinking (cognition) and functioning of people with AD. Read More
Eligibility:
-Adults ages 50-85.
-Mild to moderate Alzheimer's Disease.
-Please contact our team to learn whether you or your loved one may be a good match for this study.
Contact(s)
CONNIE BRAND
conniebr@buffalo.edu
+1 716-323-0549
Description:
This study is enrolling patients with pemphigus (vulgaris or foliaceus), a condition where the immune system attacks the skin and/or mucosa (the most superficial layer that lines body cavities and passages, for example, in your mouth). Participants are invited to take place in this study if they are newly diagnosed with pemphigus or have experienced a flareup. The goal of the study is to investigate the safety, effectiveness and tolerability of a drug compound (efgartigimod PH20 SC) in adult patients aged 18 to 80 years with pemphigus. Read More
Eligibility:
Patient has a clinical diagnosis of pemphigus vulgaris or pemphigus foliaceus which has been confirmed by cutaneous histology, positive direct immunofluorescence (IF), and positive indirect IF and/or ELISA.
Contact(s)
CATHERINE WRONA
wrona@buffalo.edu
+1 716-888-4713
Description:
This study enrolls adults with Relapsing Multiple Sclerosis. The purpose of this study is to learn about changes in cognition that happen while being treated with the experimental medication RPC1063 (also known as ozanimod). Read More
Eligibility:
- Adults ages 18-65.
- Have at least 5 years since time of RMS diagnosis.
- Have no clinically relevant cardiovascular conditions.
Contact(s)
KARA PATRICK
kpatrick@buffalo.edu
+1 716-829-5037
Description:
Researchers think the study drug, EPI-7386, may be an effective treatment for metastatic castration-resistant prostate cancer (mCRPC) because the drug works by interfering with the function of the male hormone system that leads to the growth of prostate cancer. Enzalutamide is an androgen receptor inhibitor that works by blocking the action of male hormones (androgens) like testosterone to slow down the growth of prostate cancer. Enzalutamide is approved by the Food & Drug Administration (FDA) and is commonly used as a standard of care option for men with advanced or metastatic castration-resistant prostate cancer. Since EPI-7386 and enzalutamide have not been combined together in humans, we are doing this study to find out whether EPI-7386, in combination with a fixed dose of enzalutamide, compared to standard of care enzalutamide alone, is a safe and effective treatment for men who have mCRPC. Study will be done at Spindrift Clinic location. Read More
Eligibility:
1) Males aged 18 years or older
2) Histologically, pathologically, or cytologically confirmed prostate adenocarcinoma
3) Presence of metastatic disease at study entry
4) Naïve to second generation anti-androgens
Contact(s)
Kyle Pasquariello
kylepasq@buffalo.edu
Description:
We are doing this study to learn more about if the combination of medications (durvalumab, tremelimumab and enfortumab vedotin)before and after bladder removal surgery will work and be safe for the treatment of muscle invasive bladder cancer. Also to better understand the disease and associated health problems. Read More
Eligibility:
1) Participant must be 18 or older years at the time of screening
2) Histologically or cytologically documented muscle-invasive TCC of the bladder with clinical stage of T2-4aN0-N1M0
3) Medically fit for cystectomy and able to receive neoadjuvant therapy
4) Cisplatin-ineligible
Contact(s)
Jessica McCarthy
jm279@buffalo.edu
Description:
The purpose of this study is to learn more about the advantages and disadvantages of two brief quitting smoking approaches that could be cost-effective in assisting individuals who suffer from serious mental illness. The first approach is brief advice combined with the use of nicotine gum and patches. The second approach uses an app on your smartphone combined with the use of nicotine gum and patches. Read More
Eligibility:
Inclusion Criteria
(1) Current DSM-5 diagnosis of schizophrenia, schizoaffective, bipolar, or recurring major depressive disorder;
(2) Functional impairment as indicated by a score of_2 or greater on the WHODAS 8 item version
(3) Smoker as indicated by smoking  5 cigarettes per day over the past 6 months;
(4) Desire to quit smoking as indicated by self-reported serious...
Contact(s)
Constance Duerr
cduerr@buffalo.edu
+1 716-829-6699 ext. 1
Description:
This study is to evaluate the long-term safety and tolerability of daily valbenazine (20, 40, 60, or 80mg) for the treatment of chorea associated with Huntington's Disease (HD) for up to 104 weeks. This study will enroll approximately 120 medically stable male and female subjects with HD who previously completed study drug dosing during the maintenance period as well as the study visit at Week 14 for Study NBI-98854-HD3005. Read More
Eligibility:
To participate in this study, subjects must meet the following criteria:
1. Participated in Study NBI-98854-HD3005 and
a) Study drug dosing completion of Study NBI-98854-HD3005, as demonstrated by completed study drug dosing during the dose maintenance period as well as the study visit at Week 14.
b) Early terminated Study NBI-98854-HD3005 for administrative reasons due to COVID-19...
Contact(s)
Tia Warrick
tiawarri@buffalo.edu
Description:
This study will measure the change in blood pressure following 4 months of testosterone therapy with Natesto. A total of 218 subjects with a diagnosis of hypogonadism who successfully complete the 24-hour baseline blood pressure session will be included in the study. The total duration of study will be approximately 4 months. Compensation / Reimbursement to study participants. Read More
Eligibility:
1. Male between 18 and 80 years of age, inclusive, with documented onset of hypogonadism prior to age 65. 2. Serum total testosterone < 300 ng/dL based on 2 consecutive blood samples obtained no greater than 1-4 weeks apart between 6 and 10 AM following an appropriate washout of current androgen replacement therapy if not testosterone naive. Historical values from the past 6 months may be use...
Contact(s)
Arsalan Mustafa
arsalanm@buffalo.edu
+1 716-548-9493
Description:
We plan to collect urine samples from patients with Parkinson's Disease, from which we can model the Parkinson's brain. Genetically, the neurons we generate from the urine will match that of the patient donor, making them an ideal way to screen for markers of disease. We will use our urine-derived neurons to assess differences between patient and healthy control cells, as well as a comparison of time-points from individual patients. This study will allow us to gain a clearer understanding of the altered neurochemical state that is so difficult to assess in Parkinson’s patients. Read More
Eligibility:
Diagnosis of Parkinson's Disease (or spousal control), either with or without resting tremor Aged between 40 and 99 years of age English speaking Absence of renal disease
Contact(s)
Emily Fisher
efisher5@buffalo.edu
+1 716-829-2738
Showing 31 - 40 of 316 Clinical Trials
Not finding what you are looking for? Add your profile to the Buffalo Research Registry or ResearchMatch to be matched with future studies.